ImmuCell Corporation

ICCC Healthcare Biotechnology

ImmuCell Corporation’s revenue for fiscal 2025 (year ended December 2025) was $27.6 million, up 4.34% from fiscal 2024.

Revenue
+11.5%
EPS
+233.3%
Free cash flow
+54.9%
Total debt
−15.3%

Quarter to June 2026, against a year earlier

9.90 0.05 −0.50%
Market cap
$90.4M
P/E
117×
Fwd P/E
−779×
Dividend yield
—
F-score
7/9
Altman Z
2.80
Beneish M
−3.10
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 43.18
Piotroski F-Score
7 7 1 1 7 5 7 2 2 2
Altman Z-Score
2.80 1.75 1.04 2.30 3.77 2.57 2.68 2.39 2.95 4.20
P/S ratio
2.01 1.59 2.22 2.70 3.16 2.80 2.56 3.52 3.92 2.63
P/FCF ratio
44.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
2.93 1.92 0.71 3.00 4.67 3.55 4.56 2.42 3.40 7.82
Beneish M-Score
(3.10) (2.23) (1.58) (2.61) (2.20) (0.67) (2.13) (3.31) (2.31) (2.14)
P/Operating CF
115.05 (13,568.09) (53.58) (38.67) 103.31 274.58 (753.60) (279.67) 123.76 (67.59)
P/B ratio
2.05 1.53 1.55 1.65 1.86 1.52 1.21 1.78 1.73 1.28
EV/Sales
2.20 1.84 2.85 2.94 3.10 2.90 2.53 4.18 4.42 1.84
EV/EBITDA
13.72 44.82 0.00 278.42 21.89 41.57 26.13 504.64 69.66 10.36
EV/FCF
48.22 (472.81) (7.58) (9.92) (36.41) (16.40) (49.11) (21.33) (2.79) (4.64)
Current Ratio
4.26 3.41 2.73 4.56 6.42 5.50 5.29 2.50 3.64 6.97
Net Debt/EBITDA
1.19 6.22 (3.65) 22.61 (0.38) 1.45 (0.26) 79.61 7.79 (4.50)
Debt/Equity
0.34 0.38 0.48 0.34 0.28 0.34 0.29 0.45 0.38 0.15
ROE
(3.81%) (8.21%) (20.86%) (7.92%) (0.26%) (3.57%) (5.11%) (10.24%) (0.78%) 3.35%
ROA
(2.37%) (4.85%) (13.03%) (5.58%) (0.18%) (2.59%) (3.63%) (6.93%) (0.57%) 2.59%
ROIC
3.19% (2.99%) (9.98%) (4.13%) 0.51% (2.89%) (2.08%) (3.12%) (0.53%) 4.59%
Return on Tangible Assets
(3.06%) (5.99%) (16.57%) (6.34%) (0.19%) (2.78%) (3.60%) (7.77%) (0.53%) 2.30%
Average Days of Receivables
45.14 51.95 45.66 34.57 51.10 42.75 43.55 30.97 47.03 37.95
Earnings Yield
(1.71%) (5.63%) (15.00%) (5.00%) (0.13%) (2.35%) (3.69%) (6.10%) (0.48%) 2.32%
Free Cash Flow Yield
2.27% (0.25%) (16.94%) (10.98%) (2.70%) (6.32%) (2.02%) (5.57%) (40.41%) (15.02%)
Free Cash Flow per Share
0.14 (0.01) (0.85) (0.71) (0.22) (0.38) (0.10) (0.39) (3.34) (0.89)
Book value per Share
3.00 3.37 3.23 3.92 4.29 3.92 4.25 3.96 4.77 4.67
Free Cash Flow
1.26 (0.10) (6.56) (5.51) (1.64) (2.71) (0.71) (2.15) (16.54) (3.78)
EV/EBIT
36.87 0.00 0.00 0.00 231.90 0.00 0.00 0.00 0.00 19.69
Other line items

Show all line items

Columns are period end dates